Last reviewed · How we verify
Metronidazol — Competitive Intelligence Brief
marketed
Thioredoxin reductase
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Metronidazol (Metronidazol) — University of Oslo.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Metronidazol TARGET | Metronidazol | University of Oslo | marketed | Thioredoxin reductase | ||
| Trisenox | Trisenox | German AML Cooperative Group | marketed | Potassium voltage-gated channel subfamily H member 2, Thioredoxin reductase 1, cytoplasmic |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Metronidazol CI watch — RSS
- Metronidazol CI watch — Atom
- Metronidazol CI watch — JSON
- Metronidazol alone — RSS
Cite this brief
Drug Landscape (2026). Metronidazol — Competitive Intelligence Brief. https://druglandscape.com/ci/metronidazol. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab